Is AOD-9604 Legal in New York?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide corresponding to amino acids 176 through 191 of the C-terminal region of human growth hormone. Researchers isolated this fragment because it appeared to retain the fat-metabolizing properties of hGH without stimulating IGF-1 production or promoting the glucose-raising effects associated with full-length growth hormone. Ng et al. (2000) published early work showing the fragment's lipolytic activity in animal models.

Why People Use It

Clinicians and patients interested in AOD-9604 are typically seeking body-composition support, specifically a reduction in adipose tissue, without the anabolic or diabetogenic side effects of exogenous hGH. Because it does not bind the growth hormone receptor in the same way as full-length hGH, it bypasses several of hGH's known risks. That distinction is relevant to how regulators categorize it, but it has not translated into FDA approval for any indication.

GRAS Designation: What It Does and Does Not Mean

In 2014, the FDA granted AOD-9604 a GRAS (Generally Recognized as Safe) designation specifically for use as a food ingredient at low doses. The FDA's GRAS notification database records this as GRN 000530. GRAS status for food is not the same as drug approval. A substance can be GRAS as a food additive while simultaneously being subject to drug-approval requirements if it is marketed for therapeutic purposes. The distinction matters enormously in New York and every other state.

The Federal Regulatory Framework That Controls Access in Every State

Federal law sets the floor for AOD-9604 access in New York. No state, including New York, can grant access that federal law prohibits outright.

FDA Approval Status

AOD-9604 has never completed an FDA new drug application (NDA). Metabolic Pharmaceuticals Ltd. Ran Phase 1, Phase 2, and Phase 3 trials between roughly 2001 and 2007. A Phase 3 trial in obese adults (METRO study, N=495) failed to meet its primary weight-loss endpoint at doses up to 1 mg/day orally. ClinicalTrials.gov records several of these studies under NCT identifiers including NCT00146068. After the Phase 3 failure, no sponsor pursued NDA approval, leaving AOD-9604 without an approved drug application anywhere in the United States.

Because it lacks NDA approval, selling or distributing AOD-9604 as a finished drug product to end consumers is prohibited under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act, codified in relevant part at 21 U.S.C. § 331, prohibits the introduction of unapproved new drugs into interstate commerce.

503A Compounding: The Legal Pathway That Still Exists

Section 503A of the FD&C Act permits state-licensed pharmacists and physicians to compound drugs on a patient-specific basis without FDA approval, provided specific conditions are met. The FDA summarizes these requirements at its 503A guidance page. Those conditions include:

• A valid, patient-specific prescription from a licensed practitioner
• Compounding from bulk drug substances that are not on the FDA's "negative list" for 503A
• No wholesale distribution of compounded products (they must be for a specific patient)
• The pharmacy must be licensed by its state board

AOD-9604 does not appear on the FDA's current 503A "Category 1 do-not-compound" list. That creates a legal opening for 503A pharmacies to compound it. The opening is real but narrow, and clinicians should monitor FDA communications because bulk-drug nominations can close that window.

503B Outsourcing Facilities: A Stricter Standard

Section 503B outsourcing facilities can produce compounded drugs in larger batches without patient-specific prescriptions, but the FDA imposes a stricter review process. Nominated bulk substances go through a Category 1 (appropriate to compound) or Category 2 (not appropriate to compound) classification. The FDA's 503B bulk drug substances list currently places AOD-9604 in Category 2, meaning 503B outsourcing facilities may not include it in their compounded preparations under current guidance.

This distinction is clinically meaningful. A patient in New York who receives a prescription cannot fill it at a 503B outsourcing facility. They need a 503A-compliant state-licensed compounding pharmacy.

New York State Law: What It Adds (and Does Not Add)

New York State does not have a statute that specifically names AOD-9604 or creates a state-specific ban on it. Access is governed primarily by the federal framework described above, combined with New York's own pharmacy practice rules.

New York State Board of Pharmacy

The New York State Board of Pharmacy licenses pharmacies under Education Law Article 137 and 8 NYCRR Part 29. Compounding pharmacies operating in New York must comply with USP <795> standards for non-sterile preparations or USP <797> standards for sterile preparations (AOD-9604 is typically prepared as a sterile injectable or subcutaneous preparation). USP <797> standards are referenced in FDA compounding guidance documents. A New York pharmacy that compounds AOD-9604 without meeting these standards is out of compliance regardless of the federal picture.

New York Medical Practice Act

Under New York Education Law Article 131, a licensed physician, nurse practitioner, or other authorized prescriber may write a prescription for a compounded preparation if it is for a legitimate medical purpose and within the scope of their practice. There is no provision of New York law that explicitly prohibits a prescriber from ordering a compounded peptide for off-label use, provided the prescription reflects genuine clinical judgment and the patient has given informed consent.

DEA Scheduling

AOD-9604 is not listed under any schedule of the Controlled Substances Act. New York State also does not schedule it under Public Health Law Article 33. Its absence from schedule lists means there are no DEA registration requirements for practitioners prescribing it or pharmacies dispensing it, beyond ordinary pharmacy licensure.

A Practical Legal-Access Framework for New York Patients

The pathway below reflects current law as of early 2025. Regulatory status can change, and patients should confirm current rules with their prescribing clinician.

Step 1: Establish Clinical Eligibility

A New York-licensed clinician evaluates whether AOD-9604 is appropriate based on the patient's medical history, body-composition goals, contraindications, and whether the benefit-to-risk profile justifies off-label compounded use. The evaluation should be documented in the medical record because this documentation supports the legitimacy of the prescription under both state and federal standards.

Step 2: Receive a Valid Patient-Specific Prescription

The clinician writes a prescription that specifies the compound, dose, route of administration, quantity, and patient identity. Telehealth prescriptions are legal in New York for non-controlled substances, meaning a patient does not have to be seen in person, provided the prescriber meets the standard of care for a telehealth encounter under New York Public Health Law § 2999-cc.

Step 3: Fill at a 503A-Compliant Compounding Pharmacy

The prescription goes to a pharmacy holding a current New York State Board of Pharmacy license (or an out-of-state pharmacy licensed to ship to New York). That pharmacy must compound AOD-9604 from a bulk substance obtained from an FDA-registered supplier and must follow USP <797> sterile compounding standards if the preparation is injectable.

Step 4: Follow-Up and Monitoring

Compounded peptides are not subject to the same post-market surveillance as FDA-approved drugs. Monitoring is the prescribing clinician's responsibility. Standard practice involves periodic assessments of body composition, lipid panels, fasting glucose, and a review of any injection-site reactions.

What Is Not Legal: Online Vendors Without Prescriptions

A large online gray market sells AOD-9604 labeled "for research use only." These products are not legal for human consumption. Under the FD&C Act, labeling a substance "for research use only" does not exempt it from drug regulations if it is sold with the intent that buyers will use it on themselves. FDA enforcement letters have repeatedly targeted peptide vendors operating this way. Purchasing from these sources bypasses quality controls, meaning the product may contain incorrect doses, contaminants, or entirely different substances. Several independent assays of research-chemical peptide vendors have found significant batch-to-batch dosing variability.

New York residents who order from these vendors may also face personal risk under federal customs and importation rules if products are shipped from overseas.

Clinical Evidence: What the Trials Actually Show

AOD-9604's regulatory status is partly a consequence of its clinical trial history. Understanding the evidence helps New York clinicians make defensible prescribing decisions.

Phase 2 Dose-Finding Data

A 12-week, double-blind, placebo-controlled Phase 2 study in 300 obese adults tested oral AOD-9604 at doses ranging from 1 mg to 10 mg daily. The 1 mg daily group showed statistically significant weight loss compared with placebo (P<0.05), while higher doses did not outperform placebo, suggesting a non-linear dose-response curve. Obesity Research published results from related early-phase work.

Phase 3 Failure and Its Implications

The key METRO Phase 3 trial enrolled 495 overweight and obese adults across multiple sites and tested oral AOD-9604 1 mg/day over 24 weeks. The trial did not meet its primary endpoint of superior weight loss versus placebo. This failure is the primary reason no sponsor pursued FDA approval. It does not prove the compound is ineffective under all conditions, all routes of administration, or all doses, but it does mean there is no Phase 3 evidence base supporting use.

Subcutaneous vs. Oral Administration

Most current clinical interest focuses on subcutaneous injection rather than oral dosing, partly because injectable administration avoids first-pass metabolism. The 503A compounding pathway in New York most commonly produces AOD-9604 as a sterile subcutaneous injectable. Subcutaneous-specific Phase 3 data in humans does not exist as of early 2025. Clinicians citing only the oral Phase 3 data to justify injectable use are extrapolating across two different pharmacokinetic profiles, which should be disclosed to patients during informed consent.

Safety Profile from Available Studies

Across the Phase 2 and Phase 3 trials, AOD-9604 did not produce significant changes in IGF-1, fasting glucose, or insulin levels compared with placebo, which distinguishes it from full-length hGH. A 2004 Endocrinology paper by Heffernan et al. Detailed the metabolic selectivity of the 176-191 fragment in animal models. Adverse event rates were comparable to placebo in the oral trials. Injectable formulations have a thinner evidence base for safety, and injection-site reactions are the most commonly reported issue in clinical practice.

Regulatory Risk: Why the Legal Window Could Close

The FDA's process for evaluating 503A bulk drug substances is ongoing. Once the agency formally reviews AOD-9604 under its 503A Bulks List process and places it on a Category 1 negative list, compounding by 503A pharmacies would also be prohibited. The FDA's current approach to unapproved peptides is described in its 2023 guidance on compounding. Clinicians and patients in New York should track FDA announcements on this list, as access that is legal today may not remain so in 12 to 24 months.

The FDA issued a policy in 2023 stating that certain biologically active peptides, including those with known pharmacological activity, warrant closer scrutiny under the compounding framework. AOD-9604's lipolytic activity places it in a category of compounds the FDA is watching.

Prescriber Liability and Informed Consent in New York

New York clinicians writing prescriptions for compounded AOD-9604 should be aware of their professional and legal obligations.

Documenting Medical Necessity

New York Office of Professional Medical Conduct (OPMC) guidance expects that off-label prescribing be supported by documented clinical reasoning. A chart note that explains why a patient is a candidate for AOD-9604, what alternatives were considered, and what monitoring plan is in place protects the prescriber if a regulatory question arises.

Informed Consent Elements

The American Society of Anesthesiologists and other specialty bodies have noted that compounded drugs are not subject to the same lot-testing requirements as FDA-approved products. The FDA's compounding quality FAQ acknowledges this gap. An informed consent document for a New York patient receiving compounded AOD-9604 should disclose:

• The compound is not FDA-approved for any therapeutic indication
• Phase 3 oral trial data did not demonstrate efficacy above placebo
• Injectable-specific clinical trial data in humans is limited
• Batch-to-batch potency may vary compared with FDA-approved drugs
• The regulatory status could change, affecting future access

Telehealth Prescribing Specifics

New York amended its telehealth laws in 2021 to allow prescribing of non-controlled substances after a telehealth visit, provided a patient-provider relationship is established and the standard of care is met. AOD-9604 is not a controlled substance, so this pathway is available. The prescriber must still be licensed in New York and the telehealth platform must meet New York State Department of Health requirements.

How HealthRX Approaches AOD-9604 Prescribing

HealthRX clinicians follow a structured intake protocol for patients requesting peptide therapy in New York. This includes a full medical history, BMI assessment, metabolic panel, and a review of prior weight-management interventions before any compounded peptide prescription is considered. Patients with a BMI <27 without comorbidities, active malignancy, pregnancy, or a history of pituitary tumors are screened out at intake. The prescribing clinician reviews FDA bulk-drug list status at the time of prescribing, not solely at onboarding, to ensure the prescription remains compliant.